Zeria To Submit NDA For Functional Dyspepsia Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Zeria Pharmaceutical announced positive results of Japanese Phase III study of Z-338 (acotiamide) for functional dyspepsia